ClinicalTrials.gg
CompletedNCT00792636Updated Nov 23, 2016Results posted

A Study to Determine the Effect of Sumatriptan and Naproxen Sodium Combination Tablet, Sumatriptan Tablet, and Naproxen Sodium Tablet on Blood Pressure When Treating Migraine Headaches That Occur During a 6-month Period

A Phase 4 interventional study of sumatriptan and naproxen sodium combination tablet and sumatriptan tablet in Migraine Disorders, sponsored by GlaxoSmithKline. Completed at 49 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2016-11-23.

Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
407
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 28 studies in Migraine Disorders by GlaxoSmithKline — none open to participants now, none under way, none of them phase 3. Migraine Disorders · GlaxoSmithKline.

Enrollment
7th of 19
407 · median 320
Started
2008
with 4 others
Phase 4
Only one
of the 28
Registered
16th of 28
by date

Among the 28 studies in Migraine Disorders by GlaxoSmithKline, this one is the 7th largest by enrollment of the 19 interventional ones that give a count, is one of 5 that started in 2008, is the only one in phase 4, and was the 16th registered.

Migraine Disorders

1,660 studies on the registry are indexed under Migraine Disorders; 341 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

None of the 28 studies in Migraine Disorders by GlaxoSmithKline is open now. The open studies under Migraine Disorders, anywhere →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 28 studies in Migraine Disorders by GlaxoSmithKline as a file.
02

Study summary

The purpose of this study is to test the effect on blood pressure of sumatriptan and naproxen sodium combination tablets, tablets containing only sumatriptan, and tablets containing only naproxen sodium when these drugs are taken to treat migraine headaches that occur during a 6-month period.

03

Conditions studied

  • Migraine Disorders

Browse trials for

Keywords

  • sumatriptan and naproxen sodium
  • migraine with or without aura
  • naproxen sodium
  • sumatriptan
  • blood pressure
  • migraine headaches
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects eligible for enrollment in the study must meet all of the following criteria:

  • Male and female outpatients 18 to 65 years of age. Female subjects are eligible for participation in the study if they are:

    • Females of non-
    • Females of childbearing potential and who have a negative urine pregnancy test at Screening and agree to use one of the GlaxoSmithKline specified highly effective methods for avoiding pregnancy. Subjects taking oral must be on a stable regimen for at least two months prior to Screening.
  • Subject with migraines, with or without aura (ICHD-II criteria, 1.2.1 or 1.1) [International Headache Society, 2004]. Subject must have a history of two to eight attacks per month, on average, for the six months prior to the Screening Visit. Additionally the subject is to have experienced at least two, but no more than eight, migraine attacks per month for the three months prior to Screening Visit.
  • Subject is able to distinguish migraine attacks from other headaches (i.e. tension-type headaches).
  • Subject is willing and able to provide written , to comprehend and perform the requirements of the protocol.

Exclusion criteria

Exclusion criteria:

Subjects meeting any of the following criteria must not be enrolled in the study:

  • Subject has ≥10 migraine attacks or ≥15 headache days per month in total (including migraine, probable migraine or tension-type headache).
  • Subject has retinal (ICHD-II 1.4), basilar (ICHD-II 1.2.6), or hemiplegic migraine (ICHD-II 1.2.4), or secondary headaches [International Headache Society, 2004].
  • Subject has a history of controlled or uncontrolled hypertension or is currently taking any angiotension-converting enzyme (ACE) inhibitor or angiotension receptor blocker.
  • Subject has an in-clinic screening blood pressure of ≥ 130/85 mmHg in two out of three blood pressure measurements.
  • Subject is taking any anti-hypertensive medication for any reason including for migraine prophylaxis.
  • Subject has a glycosylated ≥ 8.0
  • Subject has a chronic condition (i.e. osteoarthritis, rheumatoid arthritis,fibromyalgia) which requires chronic daily administration of non-steroidal anti-inflammatory drugs (NSAIDS) (including acetaminophen) or opioids or opioid combination products.
  • Subject, in the investigator's opinion, is likely to have unrecognized cardiovascular or cerebrovascular disease.
  • Subject has a history of congenital heart disease, cardiac arrhythmias requiring medication, or a history of a abnormality that, in the investigator's opinion, contraindicates participation in the study.
  • Subject has evidence or history of any ischemic vascular diseases including: ischemic heart disease, ischemic abdominal syndromes, peripheral vascular disease or Raynaud's Syndrome, or any signs or symptoms consistent with any of the above.
  • Subject has evidence or history of central nervous system pathology including stroke and/or (TIAs), epilepsy or structural brain lesions which lower the convulsive threshold, or has been treated with an antiepileptic drug for seizure control within five years prior to Screening.
  • Subject has a history of impaired hepatic or renal function that, in the investigator's opinion, contraindicates participation in the study.
  • Subject has , allergy, intolerance or to the use of any triptan, NSAID, or aspirin (including all sumatriptan and naproxen preparations) or has nasal polyps and asthma.
  • Subject is currently taking, or has used, an ergot or ergot-derived medication in the previous three months for migraine prophylaxis or is taking a medication that is not stabilized (i.e. change of a dose within the past two months) for chronic or intermittent migraine prophylaxis or for a co-morbid condition that is not stabilized.
  • Subject has a recent history of regular use of opioids or barbiturates for the treatment of their migraine headache and/or other non-migraine pain. Regular use is defined as an average of four days per month over the last six months.
  • Subject has taken or plans to take a monoamine oxidase inhibitor (MAOI), including herbal preparations containing St. John's Wort (Hypericum perforatum) or a CNS stimulant medication (such as atomoxetine, dextroamphetamine and amephetamine products, dexmethlyphenidate, lisdexamdetamine dimesylate and methylphenidate) anytime within two weeks prior to Screening through two-weeks post-treatment.
  • Subject has a history of any bleeding disorder or is currently taking any anticoagulant or any anti- agent. (except low-dose aspirin \<=325mg/day for cardioprotective reasons).
  • Subject has evidence or history of any gastrointestinal surgery, gastrointestinal ulceration or perforation in the past six months, gastrointestinal bleeding in the past year, or evidence or history of inflammatory bowel disease.
  • Subject is pregnant, actively trying to become pregnant, or breast feeding or subject is not willing to have pregnancy tests performed as required.
  • Subject tests positive for illicit substances on toxicology screen or has evidence of alcohol or substance abuse within the last year, or any concurrent medical or psychiatric condition which, in the investigator's judgment, will likely interfere with the study conduct, subject cooperation, or evaluation and interpretation of the study results, or which otherwise contraindicates participation in this clinical trial.
  • Subject has participated in an drug trial within the previous four weeks or plans to participate in another study at any time during the study.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
407 participants (actual)

Study arms

  • Experimental
    sumatriptan and naproxen sodium combination

    Drug: sumatriptan and naproxen sodium combination tablet

  • Active comparator
    sumatriptan

    Drug: sumatriptan tablet

  • Active comparator
    naproxen sodium

    Drug: naproxen sodium tablet

Interventions

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline in Systolic and Diastolic Blood Pressure at Month 6 for Sumatriptan/Naproxen

    The calculation of baseline and post-baseline mean blood pressure (BP) (either systolic or diastolic) for each month (30-day period) is the average of all valid Telephonic Self-Measured Blood Pressure (T-SMBP) measurements. T-SMBP technology is a method that allows the participant to self-measure BP outside the clinic using a BP monitor and transfer the data from their home to a central server. Change from baseline was calculated as the Month 6 value minus the Baseline value. Least squares mean and confidence intervals were based on mixed model repeated measures analysis (MMRM).

    Time frame: Baseline and Month 6

Secondary outcomes

  1. Mean Change From Baseline in Systolic and Diastolic Blood Pressure at Month 6 for Sumatriptan and Naproxen

    The calculation of baseline and post-baseline mean BP (either systolic or diastolic) for each month (30-day period) is the average of all valid Telephonic Self-Measured Blood Pressure (T-SMBP) measurements. T-SMBP technology is a method that allows the participant to self-measure BP outside the clinic using a BP monitor and transfer the data from their home to a central server. Change from baseline was calculated as the Month 6 value minus the Baseline value. Least squares mean and confidence intervals were based on mixed model repeated measures analysis (MMRM).

    Time frame: Baseline and Month 6

  2. Treatment Difference in Systolic and Diastolic Blood Pressure Mean Changes From Baseline at 6 Months Between Sumatriptan/Naproxen and Sumatriptan

    The calculation of baseline and post-baseline mean BP (either systolic or diastolic) for each month (30-day period) is the average of all valid Telephonic Self-Measured Blood Pressure (T-SMBP) measurements. T-SMBP technology is a method that allows the participant to self-measure BP outside the clinic using a BP monitor and transfer the data from their home to a central server. Change from baseline was calculated as the Month 6 value minus the Baseline value. Least squares mean and confidence intervals were based on mixed model repeated measures analysis (MMRM).

    Time frame: Baseline and Month 6

  3. Treatment Difference in Systolic and Diastolic Blood Pressure Mean Changes From Baseline at 6 Months Between Sumatriptan/Naproxen and Naproxen

    The calculation of baseline and post-baseline mean BP (either systolic or diastolic) for each month (30-day period) is the average of all valid Telephonic Self-Measured Blood Pressure (T-SMBP) measurements. T-SMBP technology is a method that allows the participant to self-measure BP outside the clinic using a BP monitor and transfer the data from their home to a central server. Change from baseline was calculated as the Month 6 value minus the Baseline value. Least squares mean and confidence intervals were based on mixed model repeated measures analysis (MMRM).

    Time frame: Baseline and Month 6

  4. Mean Change From Baseline in Systolic and Diastolic Blood Pressure at Month 6 for Sumatriptan/Naproxen for the ITT Subpopulation of Participants Treating, on Average, <4 Migraines, 4-6 Migraines, >=4 Migraines, and >6 Migraines Per Month

    The calculation of baseline and post-baseline mean BP (either systolic or diastolic) for each month (30-day period) is the average of all valid T-SMBP measurements. The subgrouping of the ITT population was created and examined to demonstrate the robustness of the results for the primary analysis.Descriptive statistics were calculated for baseline, month 6, and change from baseline to month 6. LSMeans and corresponding confidence intervals were based on MMRM analysis. LSMeans and corresponding confidence intervals were not calculated for \> 6 migraines/month group due to lack of convergence.

    Time frame: Baseline and Month 6

  5. Mean Change From Baseline in Systolic and Diastolic Blood Pressure at Month 6 for Sumatriptan/Naproxen for the ITT Subpopulation of Participants Treating, on Average, <1.3 Times Per Migraine, 1.3-1.7 Times Per Migraine, and >1.7 Times Per Migraine

    The calculation of baseline and post-baseline mean BP (either systolic or diastolic) for each month (30-day period) is the average of all valid T-SMBP measurements. The subgrouping of the ITT population was created and examined to demonstrate the robustness of the results for the primary analysis.Descriptive statistics were calculated for baseline, month 6, and change from baseline to month 6. LSMeans and corresponding confidence intervals were based on MMRM analysis.

    Time frame: Baseline and Month 6

  6. Mean Change From Baseline in Systolic and Diastolic Blood Pressure at Month 6 for Sumatriptan/Naproxen for the ITT Subpopulation of Participants Treating, on Average, With <6, 6-10, >=6, 10-14, and >14 Doses Per Month

    The calculation of baseline and post-baseline mean BP (either systolic or diastolic) for each month (30-day period) is the average of all valid T-SMBP measurements. The subgrouping of the ITT population was created and examined to demonstrate the robustness of the results for the primary analysis. Descriptive statistics were calculated for baseline, month 6, and change from baseline to month 6. LSMeans and corresponding confidence intervals (CIs) were based on MMRM analysis. LSMeans and CIs were not calculated for the 10-14 and the \>14 doses/month groups due to lack of convergence.

    Time frame: Baseline and Month 6

  7. Mean Change From Baseline in Systolic and Diastolic Blood Pressure at Month 6 for Sumatriptan/Naproxen for the ITT Subpopulation of Participants Treating With <30 Total Doses, 30-60 Total Doses, >=30, 60-90 Total Doses, and >90 Total Doses

    The calculation of baseline and post-baseline mean BP (either systolic or diastolic) for each month (30-day period) is the average of all valid T-SMBP measurements. The subgrouping of the ITT population was created and examined to demonstrate the robustness of the results for the primary analysis. Descriptive statistics were calculated for baseline, month 6, and change from baseline to month 6. LSMeans and corresponding confidence intervals (CIs) were based on MMRM analysis. LSMeans and CIs were not calculated for the 60-90 and the \>90 total dose groups due to lack of convergence.

    Time frame: Baseline and Month 6

  8. Number of Participants With an Increase of >=5 mmHg From the Baseline Systolic Blood Pressure for the Average of Any Given Two-day Consecutive Collection of Blood Pressure Measurements

    The number of participants with an increase of \>=5 mmHg from the baseline systolic blood pressure for the average of any given two-day consecutive collection of valid blood pressure measurements during the study were summarized. Valid blood pressure measurements were defined as follows: must be taken at least 24 hours following last dose of investigational product used to treat an individual migraine, must be taken no later than 96 hours after last dose of investigational product used to treat an individual migraine, must be taken prior to the onset of a subsequent individual migraine.

    Time frame: Baseline to End of Study (6-month study duration)

  9. Number of Participants With an Increase of >=3 mmHg From the Baseline Diastolic Blood Pressure for the Average of Any Given Two-day Consecutive Collection of Blood Pressure Measurements

    The number of participants with an increase of \>=3 mmHg from the baseline diastolic blood pressure for the average of any given two-day consecutive collection of valid blood pressure measurements during the study were summarized. Valid blood pressure measurements were defined as follows: must be taken at least 24 hours following last dose of investigational product used to treat an individual migraine, must be taken no later than 96 hours after last dose of investigational product used to treat an individual migraine, must be taken prior to the onset of a subsequent individual migraine.

    Time frame: Baseline to End of Study (6-month study duration)

  10. Number of Participants With a Consecutive 2-day Average Systolic Blood Pressure of >=140 mmHg During the Study

    The number of participants with any valid two-day consecutive average systolic blood pressure measurement of \>=140 mmHg was calculated. Valid blood pressure measurements were defined as follows: must be taken at least 24 hours following last dose of investigational product used to treat an individual migraine, must be taken no later than 96 hours after last dose of investigational product used to treat an individual migraine, must be taken prior to the onset of a subsequent individual migraine.

    Time frame: Baseline to End of Study (6-month study duration)

  11. Number of Participants With a Consecutive 2-day Average Diastolic Blood Pressure of >=90 mmHg

    The number of participants with any valid two-day consecutive average diastolic blood pressure measurement of \>=90 mmHg was calculated. Valid blood pressure measurements were defined as follows: must be taken at least 24 hours following last dose of investigational product used to treat an individual migraine, must be taken no later than 96 hours after last dose of investigational product used to treat an individual migraine, must be taken prior to the onset of a subsequent individual migraine.

    Time frame: Baseline to End of Study (6-month study duration)

  12. Time to the First Day With an Average Systolic Blood Pressure Increase of >=5 mmHg From the Baseline Systolic Blood Pressure

    Kaplan-Meier curves for the distribution of time to the first day with an average diastolic BP increase of \>=3 mmHg from the baseline diastolic BP during each calendar day were calculated and graphed for each treatment group. Only valid BP measurements were included and were defined as follows: must be taken at least 24 hours following last dose of investigational product used to treat an individual migraine, must be taken no later than 96 hours after last dose of investigational product used to treat an individual migraine, must be taken prior to the onset of a subsequent individual migraine.

    Time frame: Baseline to End of Study (6-month study duration)

  13. Time to the First Day With an Average Diastolic Blood Pressure Increase of >=3 mmHg From the Baseline Diastolic Blood Pressure

    Kaplan-Meier curves for the distribution of time to the first day with an average diastolic BP increase of \>=3 mmHg from the baseline diastolic BP during each calendar day were calculated and graphed for each treatment group. Only valid BP measurements were included and were defined as follows: must be taken at least 24 hours following last dose of investigational product used to treat an individual migraine, must be taken no later than 96 hours after last dose of investigational product used to treat an individual migraine, must be taken prior to the onset of a subsequent individual migraine.

    Time frame: Baseline to End of Study (6-month study duration)

  14. Number of Participants Withdrawn From the Study Due to Blood Pressure Changes

    The number of participants withdrawn from the study due to protocol-defined blood pressure changes were summarized for each treatment group. Defined blood pressure changes included (1) monthly average BP ≥140 mmHg systolic or \>=90 mmHg diastolic and confirmed in clinic, (2) monthly average BP increase of \>=30 mmHg systolic or \>=20 mmHg from in-clinic screening and confirmed in clinic, and (3) systolic \>=140 mmHg or diastolic \>=90 mmHg on consecutive clinic visits \>=2 weeks apart.

    Time frame: Baseline to End of Study (6-month study duration)

07

Results

Posted Nov 4, 2010

Participant flow

Participant flow — Overall Study
MilestoneSumatriptan/NaproxenSumatriptanNaproxen
Started135136136
Completed675555
Not completed688181
Withdrew: Protocol violation172320
Withdrew: Met protocol-defined stopping criteria192020
Withdrew: Lost to follow-up131914
Withdrew: Withdrew consent10139
Withdrew: Lack of efficacy3413
Withdrew: Adverse event423
Withdrew: Investigator discretion202

Outcome measures

SecondaryMean Change From Baseline in Systolic and Diastolic Blood Pressure at Month 6 for Sumatriptan and Naproxen

The calculation of baseline and post-baseline mean BP (either systolic or diastolic) for each month (30-day period) is the average of all valid Telephonic Self-Measured Blood Pressure (T-SMBP) measurements. T-SMBP technology is a method that allows the participant to self-measure BP outside the clinic using a BP monitor and transfer the data from their home to a central server. Change from baseline was calculated as the Month 6 value minus the Baseline value. Least squares mean and confidence intervals were based on mixed model repeated measures analysis (MMRM).

Time frame:
Baseline and Month 6
Reported as:
Mean · mmHg
Mean Change From Baseline in Systolic and Diastolic Blood Pressure at Month 6 for Sumatriptan and Naproxen
mmHgSumatriptanNaproxen
Systolic, Baseline, n=109, 115110.8 ± 9.15110.1 ± 9.19
Systolic, Month 6, n=42, 37109.4 ± 7.70108.2 ± 9.16
Systolic, Change from Baseline, n=41, 36-2.8 ± 5.69-1.8 ± 6.53
Diastolic, Baseline, n=109, 11575.7 ± 7.3874.7 ± 7.00
Diastolic, Month 6, n=42, 3773.9 ± 7.0374.3 ± 8.47
Diastolic, Change from Baseline, n=41, 36-1.6 ± 4.21-0.6 ± 5.50
Statistical analysis
  • Sumatriptan · Least-squares mean: -1.7 · 95% CI -3.2 to -0.3Systolic Blood Pressure. The following covariates were used in this analysis: Age, Gender, Baseline migraines per month, Baseline blood pressure
  • Sumatriptan · Least-squares mean: -0.9 · 95% CI -2.2 to 0.3Diastolic Blood Pressure. The following covariates were used in this analysis: Age, Gender, Baseline migraines per month, Baseline blood pressure
  • Naproxen · Least-squares mean: -1.9 · 95% CI -3.4 to -0.4Systolic Blood Pressure. The following covariates were used in this analysis: Age, Gender, Baseline migraines per month, Baseline blood pressure
  • Naproxen · Least-squares mean: -0.7 · 95% CI -2.0 to 0.6Diastolic blood pressure. The following covariates were used in this analysis: Age, Gender, Baseline migraines per month, Baseline blood pressure
PrimaryMean Change From Baseline in Systolic and Diastolic Blood Pressure at Month 6 for Sumatriptan/Naproxen

The calculation of baseline and post-baseline mean blood pressure (BP) (either systolic or diastolic) for each month (30-day period) is the average of all valid Telephonic Self-Measured Blood Pressure (T-SMBP) measurements. T-SMBP technology is a method that allows the participant to self-measure BP outside the clinic using a BP monitor and transfer the data from their home to a central server. Change from baseline was calculated as the Month 6 value minus the Baseline value. Least squares mean and confidence intervals were based on mixed model repeated measures analysis (MMRM).

Time frame:
Baseline and Month 6
Reported as:
Mean · millimeters of mercury (mmHg)
Mean Change From Baseline in Systolic and Diastolic Blood Pressure at Month 6 for Sumatriptan/Naproxen
millimeters of mercury (mmHg)Sumatriptan/Naproxen
Systolic, Baseline, n=120111.7 ± 9.00
Systolic, Month 6, n=48107.1 ± 9.59
Systolic, Change from Baseline, n=47-2.9 ± 5.24
Diastolic, Baseline, n=12076.0 ± 6.83
Diastolic, Month 6, n=4873.0 ± 6.84
Diastolic, Change from Baseline, n=47-2.1 ± 4.44
Statistical analysis
  • Sumatriptan/Naproxen · Least-squares mean: -2.1 · 95% CI -3.4 to -0.8Systolic blood pressure. The following covariates were used in this analysis: Age, Gender, Baseline migraines per month, Baseline blood pressure
  • Sumatriptan/Naproxen · Least-squares mean: -1.5 · 95% CI -2.6 to -0.3Diastolic blood pressure. The following covariates were used in this analysis: Age, Gender, Baseline migraines per month, Baseline blood pressure
SecondaryTreatment Difference in Systolic and Diastolic Blood Pressure Mean Changes From Baseline at 6 Months Between Sumatriptan/Naproxen and Sumatriptan

The calculation of baseline and post-baseline mean BP (either systolic or diastolic) for each month (30-day period) is the average of all valid Telephonic Self-Measured Blood Pressure (T-SMBP) measurements. T-SMBP technology is a method that allows the participant to self-measure BP outside the clinic using a BP monitor and transfer the data from their home to a central server. Change from baseline was calculated as the Month 6 value minus the Baseline value. Least squares mean and confidence intervals were based on mixed model repeated measures analysis (MMRM).

Time frame:
Baseline and Month 6
Reported as:
Mean · mmHg
Treatment Difference in Systolic and Diastolic Blood Pressure Mean Changes From Baseline at 6 Months Between Sumatriptan/Naproxen and Sumatriptan
mmHgSumatriptan/NaproxenSumatriptan
Systolic, Baseline, n=120, 109111.7 ± 9.00110.8 ± 9.15
Systolic, Month 6, n=48, 42107.1 ± 9.59109.4 ± 7.70
Systolic, Change from Baseline, n=47, 41-2.9 ± 5.24-2.8 ± 5.69
Diastolic, Baseline, n=120, 10976.0 ± 6.8375.7 ± 7.38
Diastolic, Month 6, n=48, 4273.0 ± 6.8473.9 ± 7.03
Diastolic, Change from Baseline, n=47, 41-2.1 ± 4.44-1.6 ± 4.21
Statistical analysis
  • Sumatriptan/Naproxen vs Sumatriptan · Least-squares mean: 0.4 · 95% CI -1.6 to 2.4Systolic Blood Pressure. The following covariates were used in this analysis: Age, Gender, Baseline migraines per month, Baseline blood pressure
  • Sumatriptan/Naproxen vs Sumatriptan · Least-squares mean: 0.5 · 95% CI -1.2 to 2.2Diastolic blood pressure. The following covariates were used in this analysis: Age, Gender, Baseline migraines per month, Baseline blood pressure
SecondaryTreatment Difference in Systolic and Diastolic Blood Pressure Mean Changes From Baseline at 6 Months Between Sumatriptan/Naproxen and Naproxen

The calculation of baseline and post-baseline mean BP (either systolic or diastolic) for each month (30-day period) is the average of all valid Telephonic Self-Measured Blood Pressure (T-SMBP) measurements. T-SMBP technology is a method that allows the participant to self-measure BP outside the clinic using a BP monitor and transfer the data from their home to a central server. Change from baseline was calculated as the Month 6 value minus the Baseline value. Least squares mean and confidence intervals were based on mixed model repeated measures analysis (MMRM).

Time frame:
Baseline and Month 6
Reported as:
Mean · mmHg
Treatment Difference in Systolic and Diastolic Blood Pressure Mean Changes From Baseline at 6 Months Between Sumatriptan/Naproxen and Naproxen
mmHgSumatriptan/NaproxenNaproxen
Systolic, Baseline, n=120, 115111.7 ± 9.00110.1 ± 9.19
Systolic, Month 6, n=48, 37107.1 ± 9.59108.2 ± 9.16
Systolic, Change from Baseline, n=47, 36-2.9 ± 5.24-1.8 ± 6.53
Diastolic, Baseline, n=120, 11576.0 ± 6.8374.7 ± 7.00
Diastolic, Month 6, n=48, 3773.0 ± 6.8474.3 ± 8.47
Diastolic, Change from Baseline, n=47, 36-2.1 ± 4.44-0.6 ± 5.50
Statistical analysis
  • Sumatriptan/Naproxen vs Naproxen · Least-squares mean: 0.3 · 95% CI -1.7 to 2.2Systolic Blood Pressure. The following covariates were used in this analysis: Age, Gender, Baseline migraines per month, Baseline blood pressure
  • Sumatriptan/Naproxen vs Naproxen · Least-squares mean: 0.8 · 95% CI -0.9 to 2.5Diastolic blood pressure. The following covariates were used in this analysis: Age, Gender, Baseline migraines per month, Baseline blood pressure
SecondaryMean Change From Baseline in Systolic and Diastolic Blood Pressure at Month 6 for Sumatriptan/Naproxen for the ITT Subpopulation of Participants Treating, on Average, <4 Migraines, 4-6 Migraines, >=4 Migraines, and >6 Migraines Per Month

The calculation of baseline and post-baseline mean BP (either systolic or diastolic) for each month (30-day period) is the average of all valid T-SMBP measurements. The subgrouping of the ITT population was created and examined to demonstrate the robustness of the results for the primary analysis.Descriptive statistics were calculated for baseline, month 6, and change from baseline to month 6. LSMeans and corresponding confidence intervals were based on MMRM analysis. LSMeans and corresponding confidence intervals were not calculated for \> 6 migraines/month group due to lack of convergence.

Time frame:
Baseline and Month 6
Reported as:
Least squares mean · mmHg
Mean Change From Baseline in Systolic and Diastolic Blood Pressure at Month 6 for Sumatriptan/Naproxen for the ITT Subpopulation of Participants Treating, on Average, <4 Migraines, 4-6 Migraines, >=4 Migraines, and >6 Migraines Per Month
mmHgSumatriptan/Naproxen
Systolic, <4 migraines per month-2.0 (-3.5 to -0.5)
Systolic, 4-6 migraines per month-3.3 (-7.0 to 0.4)
Systolic, >=4 migraines per month-3.7 (-6.7 to -0.7)
Diastolic, <4 migraines per month-1.2 (-2.5 to 0.00)
Diastolic, 4-6 migraines per month-5.3 (-9.9 to -0.6)
Diastolic, >=4 migraines per month-4.1 (-7.2 to -1.1)
SecondaryMean Change From Baseline in Systolic and Diastolic Blood Pressure at Month 6 for Sumatriptan/Naproxen for the ITT Subpopulation of Participants Treating, on Average, <1.3 Times Per Migraine, 1.3-1.7 Times Per Migraine, and >1.7 Times Per Migraine

The calculation of baseline and post-baseline mean BP (either systolic or diastolic) for each month (30-day period) is the average of all valid T-SMBP measurements. The subgrouping of the ITT population was created and examined to demonstrate the robustness of the results for the primary analysis.Descriptive statistics were calculated for baseline, month 6, and change from baseline to month 6. LSMeans and corresponding confidence intervals were based on MMRM analysis.

Time frame:
Baseline and Month 6
Reported as:
Least squares mean · mmHg
Mean Change From Baseline in Systolic and Diastolic Blood Pressure at Month 6 for Sumatriptan/Naproxen for the ITT Subpopulation of Participants Treating, on Average, <1.3 Times Per Migraine, 1.3-1.7 Times Per Migraine, and >1.7 Times Per Migraine
mmHgSumatriptan/Naproxen
Systolic, <1.3 doses per migraine-0.3 (-2.7 to 2.0)
Systolic, 1.3-1.7 doses per migraine-2.7 (-5.3 to -0.2)
Systolic, >1.7 doses per migraine-3.8 (-6.2 to -1.5)
Diastolic, <1.3 doses per migraine-0.4 (-2.2 to 1.5)
Diastolic, 1.3-1.7 doses per migraines-0.9 (-2.9 to 1.2)
Diastolic, >1.7 doses per migraine-3.2 (-5.3 to -1.0)
SecondaryMean Change From Baseline in Systolic and Diastolic Blood Pressure at Month 6 for Sumatriptan/Naproxen for the ITT Subpopulation of Participants Treating, on Average, With <6, 6-10, >=6, 10-14, and >14 Doses Per Month

The calculation of baseline and post-baseline mean BP (either systolic or diastolic) for each month (30-day period) is the average of all valid T-SMBP measurements. The subgrouping of the ITT population was created and examined to demonstrate the robustness of the results for the primary analysis. Descriptive statistics were calculated for baseline, month 6, and change from baseline to month 6. LSMeans and corresponding confidence intervals (CIs) were based on MMRM analysis. LSMeans and CIs were not calculated for the 10-14 and the \>14 doses/month groups due to lack of convergence.

Time frame:
Baseline and Month 6
Reported as:
Least squares mean · mmHg
Mean Change From Baseline in Systolic and Diastolic Blood Pressure at Month 6 for Sumatriptan/Naproxen for the ITT Subpopulation of Participants Treating, on Average, With <6, 6-10, >=6, 10-14, and >14 Doses Per Month
mmHgSumatriptan/Naproxen
Systolic,<6 doses per month-1.6 (-3.1 to 0.0)
Systolic, 6-10 doses per month-4.6 (-7.4 to -1.8)
Systolic, >=6 doses per month-4.3 (-7.1 to -1.6)
Diastolic,<6 doses per month-1.0 (-2.2 to 0.3)
Diastolic, 6-10 doses per month-3.7 (-7.1 to -0.4)
Diastolic, >=6 doses per month-3.5 (-6.3 to -0.7)
SecondaryMean Change From Baseline in Systolic and Diastolic Blood Pressure at Month 6 for Sumatriptan/Naproxen for the ITT Subpopulation of Participants Treating With <30 Total Doses, 30-60 Total Doses, >=30, 60-90 Total Doses, and >90 Total Doses

The calculation of baseline and post-baseline mean BP (either systolic or diastolic) for each month (30-day period) is the average of all valid T-SMBP measurements. The subgrouping of the ITT population was created and examined to demonstrate the robustness of the results for the primary analysis. Descriptive statistics were calculated for baseline, month 6, and change from baseline to month 6. LSMeans and corresponding confidence intervals (CIs) were based on MMRM analysis. LSMeans and CIs were not calculated for the 60-90 and the \>90 total dose groups due to lack of convergence.

Time frame:
Baseline and Month 6
Reported as:
Least squares mean · mmHg
Mean Change From Baseline in Systolic and Diastolic Blood Pressure at Month 6 for Sumatriptan/Naproxen for the ITT Subpopulation of Participants Treating With <30 Total Doses, 30-60 Total Doses, >=30, 60-90 Total Doses, and >90 Total Doses
mmHgSumatriptan/Naproxen
Systolic, <30 total doses-1.2 (-2.9 to 0.4)
Systolic, 30-60 total doses-3.4 (-6.0 to -0.7)
Systolic, >=30 total doses-3.7 (-6.0 to -1.4)
Diastolic, <30 total doses-0.6 (-2.0 to 0.7)
Diastolic, 30-60 total doses-3.3 (-5.8 to -0.8)
Diastolic, >=30 total doses-3.6 (-5.7 to -1.4)
SecondaryNumber of Participants With an Increase of >=5 mmHg From the Baseline Systolic Blood Pressure for the Average of Any Given Two-day Consecutive Collection of Blood Pressure Measurements

The number of participants with an increase of \>=5 mmHg from the baseline systolic blood pressure for the average of any given two-day consecutive collection of valid blood pressure measurements during the study were summarized. Valid blood pressure measurements were defined as follows: must be taken at least 24 hours following last dose of investigational product used to treat an individual migraine, must be taken no later than 96 hours after last dose of investigational product used to treat an individual migraine, must be taken prior to the onset of a subsequent individual migraine.

Time frame:
Baseline to End of Study (6-month study duration)
Reported as:
Number · participants
Number of Participants With an Increase of >=5 mmHg From the Baseline Systolic Blood Pressure for the Average of Any Given Two-day Consecutive Collection of Blood Pressure Measurements
participantsSumatriptan/NaproxenSumatriptanNaproxen
Number of Participants With an Increase of >=5 mmHg From the Baseline Systolic Blood Pressure for the Average of Any Given Two-day Consecutive Collection of Blood Pressure Measurements535763
Statistical analysis
  • Sumatriptan/Naproxen vs Sumatriptan · Odds ratio (or): 1.5 · 95% CI 0.9 to 2.6
  • Sumatriptan/Naproxen vs Naproxen · Odds ratio (or): 1.5 · 95% CI 0.9 to 2.6
SecondaryNumber of Participants With an Increase of >=3 mmHg From the Baseline Diastolic Blood Pressure for the Average of Any Given Two-day Consecutive Collection of Blood Pressure Measurements

The number of participants with an increase of \>=3 mmHg from the baseline diastolic blood pressure for the average of any given two-day consecutive collection of valid blood pressure measurements during the study were summarized. Valid blood pressure measurements were defined as follows: must be taken at least 24 hours following last dose of investigational product used to treat an individual migraine, must be taken no later than 96 hours after last dose of investigational product used to treat an individual migraine, must be taken prior to the onset of a subsequent individual migraine.

Time frame:
Baseline to End of Study (6-month study duration)
Reported as:
Number · participants
Number of Participants With an Increase of >=3 mmHg From the Baseline Diastolic Blood Pressure for the Average of Any Given Two-day Consecutive Collection of Blood Pressure Measurements
participantsSumatriptan/NaproxenSumatriptanNaproxen
Number of Participants With an Increase of >=3 mmHg From the Baseline Diastolic Blood Pressure for the Average of Any Given Two-day Consecutive Collection of Blood Pressure Measurements726577
Statistical analysis
  • Sumatriptan/Naproxen vs Sumatriptan · Odds ratio (or): 1.0 · 95% CI 0.6 to 1.7
  • Sumatriptan/Naproxen vs Naproxen · Odds ratio (or): 1.3 · 95% CI 0.7 to 2.2
SecondaryNumber of Participants With a Consecutive 2-day Average Systolic Blood Pressure of >=140 mmHg During the Study

The number of participants with any valid two-day consecutive average systolic blood pressure measurement of \>=140 mmHg was calculated. Valid blood pressure measurements were defined as follows: must be taken at least 24 hours following last dose of investigational product used to treat an individual migraine, must be taken no later than 96 hours after last dose of investigational product used to treat an individual migraine, must be taken prior to the onset of a subsequent individual migraine.

Time frame:
Baseline to End of Study (6-month study duration)
Reported as:
Number · participants
Number of Participants With a Consecutive 2-day Average Systolic Blood Pressure of >=140 mmHg During the Study
participantsSumatriptan/NaproxenSumatriptanNaproxen
Number of Participants With a Consecutive 2-day Average Systolic Blood Pressure of >=140 mmHg During the Study223
Statistical analysis
  • Sumatriptan/Naproxen vs Sumatriptan · Odds ratio (or): 1.0 · 95% CI 0.1 to 13.6
  • Sumatriptan/Naproxen vs Naproxen · Odds ratio (or): 2.8 · 95% CI 0.3 to 25.6
SecondaryNumber of Participants With a Consecutive 2-day Average Diastolic Blood Pressure of >=90 mmHg

The number of participants with any valid two-day consecutive average diastolic blood pressure measurement of \>=90 mmHg was calculated. Valid blood pressure measurements were defined as follows: must be taken at least 24 hours following last dose of investigational product used to treat an individual migraine, must be taken no later than 96 hours after last dose of investigational product used to treat an individual migraine, must be taken prior to the onset of a subsequent individual migraine.

Time frame:
Baseline to End of Study (6-month study duration)
Reported as:
Number · participants
Number of Participants With a Consecutive 2-day Average Diastolic Blood Pressure of >=90 mmHg
participantsSumatriptan/NaproxenSumatriptanNaproxen
Number of Participants With a Consecutive 2-day Average Diastolic Blood Pressure of >=90 mmHg101111
Statistical analysis
  • Sumatriptan/Naproxen vs Sumatriptan · Odds ratio (or): 1.4 · 95% CI 0.5 to 3.7
  • Sumatriptan/Naproxen vs Naproxen · Odds ratio (or): 1.6 · 95% CI 0.6 to 4.2
SecondaryTime to the First Day With an Average Systolic Blood Pressure Increase of >=5 mmHg From the Baseline Systolic Blood Pressure

Kaplan-Meier curves for the distribution of time to the first day with an average diastolic BP increase of \>=3 mmHg from the baseline diastolic BP during each calendar day were calculated and graphed for each treatment group. Only valid BP measurements were included and were defined as follows: must be taken at least 24 hours following last dose of investigational product used to treat an individual migraine, must be taken no later than 96 hours after last dose of investigational product used to treat an individual migraine, must be taken prior to the onset of a subsequent individual migraine.

Time frame:
Baseline to End of Study (6-month study duration)
Reported as:
Median · days
Time to the First Day With an Average Systolic Blood Pressure Increase of >=5 mmHg From the Baseline Systolic Blood Pressure
daysSumatriptan/NaproxenSumatriptanNaproxen
Time to the First Day With an Average Systolic Blood Pressure Increase of >=5 mmHg From the Baseline Systolic Blood Pressure42.5 (2 to 177)32.5 (3 to 118)18.5 (3 to 124)
Statistical analysis
  • Sumatriptan/Naproxen vs Sumatriptan · Hazard ratio (hr): 1.14 · 95% CI 0.84 to 1.54
  • Sumatriptan/Naproxen vs Naproxen · Hazard ratio (hr): 1.36 · 95% CI 1.01 to 1.83
SecondaryTime to the First Day With an Average Diastolic Blood Pressure Increase of >=3 mmHg From the Baseline Diastolic Blood Pressure

Kaplan-Meier curves for the distribution of time to the first day with an average diastolic BP increase of \>=3 mmHg from the baseline diastolic BP during each calendar day were calculated and graphed for each treatment group. Only valid BP measurements were included and were defined as follows: must be taken at least 24 hours following last dose of investigational product used to treat an individual migraine, must be taken no later than 96 hours after last dose of investigational product used to treat an individual migraine, must be taken prior to the onset of a subsequent individual migraine.

Time frame:
Baseline to End of Study (6-month study duration)
Reported as:
Median · days
Time to the First Day With an Average Diastolic Blood Pressure Increase of >=3 mmHg From the Baseline Diastolic Blood Pressure
daysSumatriptan/NaproxenSumatriptanNaproxen
Time to the First Day With an Average Diastolic Blood Pressure Increase of >=3 mmHg From the Baseline Diastolic Blood Pressure51 (2 to 140)50.5 (3 to 161)26 (3 to 124)
Statistical analysis
  • Sumatriptan/Naproxen vs Sumatriptan · Hazard ratio (hr): 0.88 · 95% CI 0.65 to 1.21
  • Sumatriptan/Naproxen vs Naproxen · Hazard ratio (hr): 1.18 · 95% CI 0.88 to 1.60
SecondaryNumber of Participants Withdrawn From the Study Due to Blood Pressure Changes

The number of participants withdrawn from the study due to protocol-defined blood pressure changes were summarized for each treatment group. Defined blood pressure changes included (1) monthly average BP ≥140 mmHg systolic or \>=90 mmHg diastolic and confirmed in clinic, (2) monthly average BP increase of \>=30 mmHg systolic or \>=20 mmHg from in-clinic screening and confirmed in clinic, and (3) systolic \>=140 mmHg or diastolic \>=90 mmHg on consecutive clinic visits \>=2 weeks apart.

Time frame:
Baseline to End of Study (6-month study duration)
Reported as:
Number · participants
Number of Participants Withdrawn From the Study Due to Blood Pressure Changes
participantsSumatriptan/NaproxenSumatriptanNaproxen
Number of Participants Withdrawn From the Study Due to Blood Pressure Changes100

Adverse events

Collected over Serious adverse events (SAEs) and adverse events (AEs) were recorded from the start of investigational product and until any follow-up contact. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sumatriptan/Naproxen—3/127 (2.4%)20/127 (15.7%)
Sumatriptan—1/120 (0.8%)29/120 (24.2%)
Naproxen—0/127 (0%)18/127 (14.2%)
Most frequent serious events
Most frequent serious events
EventSumatriptan/NaproxenSumatriptanNaproxen
Abortion inducedPregnancy, puerperium and perinatal conditions0/1271/1200/127
Chest painGeneral disorders1/1270/1200/127
CellulitisInfections and infestations1/1270/1200/127
ConvulsionNervous system disorders1/1270/1200/127
DyspnoeaRespiratory, thoracic and mediastinal disorders1/1270/1200/127
Most frequent other events
Showing 10 of 11
Most frequent other events
EventSumatriptan/NaproxenSumatriptanNaproxen
NasopharyngitisInfections and infestations4/1276/1205/127
Urinary tract infectionInfections and infestations1/1276/1203/127
Upper respiratory tract infectionInfections and infestations0/1275/1201/127
DizzinessNervous system disorders5/1275/1201/127
Neck painMusculoskeletal and connective tissue disorders2/1274/1200/127
NauseaGastrointestinal disorders4/1272/1201/127
SomnolenceNervous system disorders2/1273/1202/127
Back painMusculoskeletal and connective tissue disorders2/1273/1202/127
Sinus congestionRespiratory, thoracic and mediastinal disorders0/1273/1201/127
SinusitisInfections and infestations3/1272/1201/127

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Sumatriptan/NaproxenSumatriptanNaproxenTotal
Mean39.0 ± 11.6439.8 ± 11.2239.1 ± 11.9239.3 ± 11.58
Sex: Female, Male
Sex: Female, Male(Participants)Sumatriptan/NaproxenSumatriptanNaproxenTotal
Female949896288
Male28142264
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Sumatriptan/NaproxenSumatriptanNaproxenTotal
White10896105309
African American/African Heritage12111033
Asian2338
Asian and White0101
American Indian or Alaska Native0101
Average Number of Migraine Attacks per Month
Average Number of Migraine Attacks per Month(migraines)Sumatriptan/NaproxenSumatriptanNaproxenTotal
Mean4.5 ± 1.764.2 ± 1.674.6 ± 1.84.4 ± 1.75
08

Study locations

49 sites
  • GSK Investigational Site
    Chandler, Arizona 85224, United States
  • GSK Investigational Site
    Gilbert, Arizona 85234, United States
  • GSK Investigational Site
    Litchfield Park, Arizona 85340, United States
  • GSK Investigational Site
    Phoenix, Arizona 85050, United States
  • GSK Investigational Site
    Tempe, Arizona 85283, United States
  • GSK Investigational Site
    Little Rock, Arkansas 72205, United States
  • GSK Investigational Site
    Anaheim, California 92801, United States
  • GSK Investigational Site
    Anaheim, California 92805, United States
  • GSK Investigational Site
    Buena Park, California 90620, United States
  • GSK Investigational Site
    Garden Grove, California 92845, United States
  • GSK Investigational Site
    Newport Beach, California 92660, United States
  • GSK Investigational Site
    Santa Monica, California 90404, United States
  • GSK Investigational Site
    Westlake Village, California 91361, United States
  • GSK Investigational Site
    Colorado Springs, Colorado 80904, United States
  • GSK Investigational Site
    Avon, Connecticut 06001, United States
  • GSK Investigational Site
    Hialeah, Florida 33010, United States
  • GSK Investigational Site
    Jacksonville, Florida 32216, United States
  • GSK Investigational Site
    Miami, Florida 33143, United States
  • GSK Investigational Site
    Pembroke Pines, Florida 33024, United States
  • GSK Investigational Site
    St. Petersburg, Florida 33702, United States
  • GSK Investigational Site
    Sunrise, Florida 33351, United States
  • GSK Investigational Site
    Atlanta, Georgia 30308, United States
  • GSK Investigational Site
    Decatur, Georgia 30034, United States
  • GSK Investigational Site
    Chicago, Illinois 60614, United States
  • GSK Investigational Site
    Wichita, Kansas 67207, United States
  • GSK Investigational Site
    Kalamazoo, Michigan 49009, United States
  • GSK Investigational Site
    Springfield, Missouri 65807, United States
  • GSK Investigational Site
    St. Louis, Missouri 63141, United States
  • GSK Investigational Site
    Greensboro, North Carolina 27405, United States
  • GSK Investigational Site
    Harrisburg, North Carolina 28075, United States
  • GSK Investigational Site
    Matthews, North Carolina 28105, United States
  • GSK Investigational Site
    Raleigh, North Carolina 27607, United States
  • GSK Investigational Site
    Raleigh, North Carolina 27609, United States
  • GSK Investigational Site
    Raleigh, North Carolina 27612, United States
  • GSK Investigational Site
    Winston-Salem, North Carolina 27103, United States
  • GSK Investigational Site
    Cleveland, Ohio 44122, United States
  • GSK Investigational Site
    West Chester, Ohio 45069, United States
  • GSK Investigational Site
    Oklahoma City, Oklahoma 73112, United States
  • GSK Investigational Site
    Pittsburgh, Pennsylvania 15236, United States
  • GSK Investigational Site
    Mount Pleasant, South Carolina 29464, United States
  • GSK Investigational Site
    Simpsonville, South Carolina 29681, United States
  • GSK Investigational Site
    Bristol, Tennessee 37620, United States
  • GSK Investigational Site
    Memphis, Tennessee 38018, United States
  • GSK Investigational Site
    Nashville, Tennessee 37203, United States
  • GSK Investigational Site
    Austin, Texas 78705, United States
  • GSK Investigational Site
    Houston, Texas 77004, United States
  • GSK Investigational Site
    San Antonio, Texas 78205, United States
  • GSK Investigational Site
    Salt Lake City, Utah 84107, United States
  • GSK Investigational Site
    West Jordan, Utah 84088, United States
09

References and documents

Publications

  • White WB, Derosier FJ, Thompson AH, Adams BE, Goodman DK. Evaluation of the migraine treatment sumatriptan/naproxen sodium on blood pressure following long-term administration. J Clin Hypertens (Greenwich). 2011 Dec;13(12):910-6. doi: 10.1111/j.1751-7176.2011.00554.x. Epub 2011 Nov 11. PubMed 22142350 ↗

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2008, a primary completion of Nov 2009 and a completion of Nov 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2010, 1 year after primary completion. A results delay was requested in Aug 2010.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2008
First posted
Nov 18, 2008
Start
Nov 2008
Primary completionActual
Nov 2009
CompletionActual
Nov 2009
Results delay requested
Aug 12, 2010
Results first posted
Nov 4, 2010
Last update
Nov 23, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 23, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00792636
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Nov 18, 2008
Start date
Nov 2008
Primary completion
Nov 2009
Completion
Nov 2009
Results posted
Nov 4, 2010
Last update
Nov 23, 2016

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion